CN110300755B - 茚满基氨基氮杂二氢苯并呋喃乙酸、用于治疗糖尿病的药物组合物 - Google Patents

茚满基氨基氮杂二氢苯并呋喃乙酸、用于治疗糖尿病的药物组合物 Download PDF

Info

Publication number
CN110300755B
CN110300755B CN201880010175.7A CN201880010175A CN110300755B CN 110300755 B CN110300755 B CN 110300755B CN 201880010175 A CN201880010175 A CN 201880010175A CN 110300755 B CN110300755 B CN 110300755B
Authority
CN
China
Prior art keywords
group
compound
alkyl
compounds
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880010175.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN110300755A (zh
Inventor
M·埃克哈特
H·瓦格纳
S·彼得斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN110300755A publication Critical patent/CN110300755A/zh
Application granted granted Critical
Publication of CN110300755B publication Critical patent/CN110300755B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201880010175.7A 2017-02-08 2018-02-02 茚满基氨基氮杂二氢苯并呋喃乙酸、用于治疗糖尿病的药物组合物 Active CN110300755B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17155191 2017-02-08
EP17155191.4 2017-02-08
PCT/EP2018/052620 WO2018146008A1 (en) 2017-02-08 2018-02-02 Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes

Publications (2)

Publication Number Publication Date
CN110300755A CN110300755A (zh) 2019-10-01
CN110300755B true CN110300755B (zh) 2022-10-04

Family

ID=57995116

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880010175.7A Active CN110300755B (zh) 2017-02-08 2018-02-02 茚满基氨基氮杂二氢苯并呋喃乙酸、用于治疗糖尿病的药物组合物

Country Status (5)

Country Link
US (1) US10550127B1 (https=)
EP (1) EP3580222B1 (https=)
JP (1) JP7049353B2 (https=)
CN (1) CN110300755B (https=)
WO (1) WO2018146008A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793530B2 (en) 2017-01-26 2020-10-06 Boehringer Ingelheim International Gmbh Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
WO2018138030A1 (en) 2017-01-26 2018-08-02 Boehringer Ingelheim International Gmbh Benzyloxypyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
US10919859B2 (en) 2017-01-26 2021-02-16 Boehringer Ingelheim International Gmbh Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
CN110198928B (zh) 2017-01-26 2023-08-29 勃林格殷格翰国际有限公司 苄氧基吡啶基环丙烷甲酸、其药物组合物和用途
JP7049353B2 (ja) 2017-02-08 2022-04-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
US12083118B2 (en) 2018-03-29 2024-09-10 Arbutus Biopharma Corporation Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010143733A1 (en) * 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
WO2012072691A1 (en) * 2010-12-01 2012-06-07 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
CN104321319A (zh) * 2012-03-26 2015-01-28 勃林格殷格翰国际有限公司 新的茚满基氧基二氢苯并呋喃乙酸衍生物及其用作gpr40 受体激动剂的用途
WO2015078802A1 (en) * 2013-11-28 2015-06-04 Boehringer Ingelheim International Gmbh New indanyloxyphenylcyclopropanecarboxylic acids
CN104822675A (zh) * 2012-11-28 2015-08-05 勃林格殷格翰国际有限公司 新的茚满基氧基二氢苯并呋喃乙酸
CN105001212A (zh) * 2014-04-16 2015-10-28 江苏柯菲平医药股份有限公司 稠环化合物及其制备方法和应用
WO2017042121A1 (en) * 2015-09-09 2017-03-16 Boehringer Ingelheim International Gmbh [{[2,3-dihydro-1h-inden-1-yl]amino}-2h,3h-furo[3,2-b]pyridin-3-yl]acetic acids, pharmaceutical compositions and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2505322A (en) 1945-09-14 1950-04-25 Gibson Refrigerator Co Refrigerator cabinet
US2560111A (en) 1946-11-07 1951-07-10 Raymond T Levine Buffing chuck
US2656003A (en) 1948-02-27 1953-10-20 Inst Of Inventive Res High explosive disk-shaped charge for seismic exploration
US2727340A (en) 1953-08-31 1955-12-20 Alfred S Zanotta Portable tool for reconditioning crane rails
US5356287A (en) 1987-03-16 1994-10-18 Mcintyre Kevin M Simulating presence
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
US7834013B2 (en) 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
US7664629B2 (en) 2005-07-19 2010-02-16 Xerox Corporation Second language writing advisor
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
KR20080103584A (ko) 2006-03-30 2008-11-27 아사히 가세이 파마 가부시키가이샤 치환 이환식 환상 유도체 및 그 용도
RS53230B (sr) 2006-06-27 2014-08-29 Takeda Pharmaceutical Company Limited Kondenzovana ciklična jedinjenja kao modulatori gpr40 receptora
TW200838526A (en) 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
KR20110027657A (ko) 2008-06-25 2011-03-16 다이이찌 산쿄 가부시키가이샤 카르복실산 화합물
ES2345916B1 (es) 2008-10-14 2011-09-14 Clipdorfix, S.L. Dispositivo de fijacion liberable de elementos adosados.
AU2009303475B2 (en) 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
US8633182B2 (en) 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
WO2014019186A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US20140163025A1 (en) 2012-12-07 2014-06-12 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
EP2963027B1 (en) 2013-02-28 2018-12-26 TiumBio Co., Ltd. Tricyclic compound and use thereof
CN105473595A (zh) 2013-08-23 2016-04-06 福建海西新药创制有限公司 治疗糖尿病的羧酸化合物
CN105820396A (zh) 2016-04-22 2016-08-03 宁波硫华聚合物有限公司 橡胶促进剂四硫化双五亚甲基秋兰姆预分散母胶粒及其制备方法
CN110198928B (zh) 2017-01-26 2023-08-29 勃林格殷格翰国际有限公司 苄氧基吡啶基环丙烷甲酸、其药物组合物和用途
JP7049353B2 (ja) 2017-02-08 2022-04-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010143733A1 (en) * 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
WO2012072691A1 (en) * 2010-12-01 2012-06-07 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
CN104321319A (zh) * 2012-03-26 2015-01-28 勃林格殷格翰国际有限公司 新的茚满基氧基二氢苯并呋喃乙酸衍生物及其用作gpr40 受体激动剂的用途
CN104822675A (zh) * 2012-11-28 2015-08-05 勃林格殷格翰国际有限公司 新的茚满基氧基二氢苯并呋喃乙酸
WO2015078802A1 (en) * 2013-11-28 2015-06-04 Boehringer Ingelheim International Gmbh New indanyloxyphenylcyclopropanecarboxylic acids
CN105001212A (zh) * 2014-04-16 2015-10-28 江苏柯菲平医药股份有限公司 稠环化合物及其制备方法和应用
WO2017042121A1 (en) * 2015-09-09 2017-03-16 Boehringer Ingelheim International Gmbh [{[2,3-dihydro-1h-inden-1-yl]amino}-2h,3h-furo[3,2-b]pyridin-3-yl]acetic acids, pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
EP3580222A1 (en) 2019-12-18
WO2018146008A1 (en) 2018-08-16
US20200017515A1 (en) 2020-01-16
EP3580222B1 (en) 2021-04-07
CN110300755A (zh) 2019-10-01
JP7049353B2 (ja) 2022-04-06
JP2020506205A (ja) 2020-02-27
US10550127B1 (en) 2020-02-04

Similar Documents

Publication Publication Date Title
CN110300755B (zh) 茚满基氨基氮杂二氢苯并呋喃乙酸、用于治疗糖尿病的药物组合物
CN110214135B (zh) 茚满基氨基吡嗪基环丙烷羧酸、药物组合物及其用途
JP6816107B2 (ja) インダニルアミノピリジルシクロプロパンカルボン酸、医薬組成物及びこれらの使用
CN110312706B (zh) 茚满基氨基吡啶基环丙烷甲酸、其药物组合物及用途
JP7049349B2 (ja) ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
CN110312714B (zh) 苄基氧基吡嗪基环丙烷甲酸、其药物组合物和用途
CN110088089B (zh) 苄基氨基吡啶基环丙烷甲酸、药物组合物及其用途
EP3347358B1 (en) [{[2,3-dihydro-1h-inden-1-yl]amino}-2h,3h-furo[3,2-b]pyridin-3-yl]acetic acids, pharmaceutical compositions and uses thereof
JP7023969B2 (ja) ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
CN110198928A (zh) 苄氧基吡啶基环丙烷甲酸、其药物组合物和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant